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Hypoglycemia-associated autonomic failure (HAAF) is a syndrome of acute adaptation to a metabolic
stressor, in which neuroendocrine responses to repetitive hypoglycemic bouts are blunted. The CNS
mechanisms that contribute to HAAF are unknown. In the present study, we modeled HAAF in the rat
and measured the activity of tyrosine hydroxylase (TH) as an index of acute noradrenergic activation, to
test the hypothesis that noradrenergic activation of the hypothalamus might be impaired. In association
with a significant counter-regulatory response to a single bout of hypoglycemia (elevated
corticosterone, catecholamines, and glucagon), TH activity was elevated overall in brainstem NE
cell body areas and hypothalamus. With multiple hypoglycemic episodes in a 24 h period, the counter-
regulatory response was blunted, and hypothalamic TH activity was comparable to that of saline-
infused controls. In a similar paradigm, multiple bouts of CNS neuroglucopenia did not blunt the
hyperglycemic or corticosterone responses, and were required for elevation of TH activity. This
alternate response pattern suggests that insulin-induced hypoglycemia and cerebral neuroglucopenia
represent somewhat different metabolic stressors at the CNS.
Keywords: Catecholamines; Glucocorticoids; Neuroglucopenia; Stress
INTRODUCTION
Repeated exposure to both physical and psychological
stressors can lead to stress adaptation, in which the
neuroendocrine response to the stressor is blunted
(Dallman, 1993; Garcia et al., 2000). One example of
adaptation to a physical stressor is the phenomenon of
hypoglycemia-associated autonomic failure, (HAAF)
(Heller and Cryer, 1991). One component of HAAF is
an impairment of the normal counter-regulatory response
to hypoglycemia, including deficient output of adrenal
epinephrine, glucagon from the endocrine pancreas, and
adrenal glucocorticoids. This syndrome, although charac-
terized extensively in a clinical context in insulin-
requiring diabetic patients (Tamborlane and Amiel, 1992;
Cryer, 1993; Veneman et al., 1993; Ohkubo et al., 1995),
can be modeled experimentally in normal human
subjects. It has been shown to occur when one or two
bouts of hypoglycemia are induced within 24 h of a final
(i.e. second or third) bout of hypoglycemia (Heller and
Cryer, 1991; Davis et al., 1996). Thus, although diabetic
complications may contribute to impaired counter-
regulatory responses in patients with chronic diabetes
(e.g. Bax et al., 1995; Boyle et al., 1995), it is clear that
the onset of the syndrome is due to very acute changes in
autonomic regulation of neuroendocrine responses in
individuals who have no history of abnormal autonomic
or endocrine pancreatic function. The mechanisms
underlying this acute dysregulation have not been
determined.
Recent studies have suggested that a prior history of
elevation of plasma glucocorticoid levels can play a
causative or strongly contributory role in the manifestation
of acute HAAF (Davis et al., 1996). In a two-day study
design, they infused non-diabetic human subjects with
cortisol on the first day, matching the plasma levels
normally achieved during hypoglycemia; on the second
day, patients were infused with insulin to achieve
hypoglycemia. Another group received hypoglycemic
insulin infusions on the first day. Davis and colleagues
observed that counter- regulatory responses in the subjects
who received cortisol on the first day matched or
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approximated the blunted responses observed in the group
who were hypoglycemic on both the first and second days
of the study. Thus, adrenal glucocorticoids appear to have
an acute action to blunt activation of a normal
neuroendocrine counter-regulatory response. Studies
from Pacak and colleagues have shown that the adrenal
glucocorticoids can act at the hypothalamus to blunt the
activity of the hypothalamic-pituitary-adrenal (HPA) axis
(Pacak et al., 1995a), and one mechanism for this action is
the inhibition of release of norepinephrine (NE) at the
paraventricular nucleus of the hypothalamus (PVN). NE
release and activity at the PVN are correlated with an
adrenocorticotrophin (ACTH) response to a variety of
stressors although the quantitative relationship between
NE release and plasma ACTH is stressor-specific (Pacak
et al., 1995b). It is not known, however, whether this type
of feedback impairment of NE activity can occur on an
acute basis.
In the present study, we measured brain tyrosine
hydroxylase (TH) in a rat model of acute HAAF. On a very
acute basis (minutes to hours), activity of this rate-limiting
synthetic enzyme for NE can be modulated at the nerve
terminals in response to activation of the nerves (Gold-
stein, 1995; Kumer and Vrana, 1996). Here, we measured
TH activity within the NE cell regions of the brainstem
(A1, A2, and locus coeruleus [LC]) as well as within the
hypothalamus to determine whether TH activity—
presumably reflecting acute activation of NE neurons—
is elevated in association with hypoglycemia; and to
determine whether any activation is decreased in
association with acute HAAF. Such a finding would target
brainstem NE neurons as being a vulnerable neuroanato-
mical substrate within the brain for a hypoglycemic insult.
Because lack of available glucose represents a component
of insulin-induced hypoglycemia, we administered the
neuroglucopenic agent, 5-thioglucose (5TG) into the
cerebral ventricles to generate local CNS neuroglucope-
nia, and measured TH activity in the same brain areas, to
determine whether this might be a factor influencing




Male Wistar rats (Simonson, CA; 250–400 gm) were
studied. Rats were maintained on a 12–12 h light-dark
schedule (lights on at 7 a.m., off at 7 p.m.), with ad libitum
access to food and water. All procedures were approved
by the Institutional Animal Care and Use Committee of
the VA Puget Sound Health Care System.
Surgery
Rats in the hypoglycemia study received bilateral
intravenous (IV) silastic catheters according to the method
of Scheurink et al. (1990) under ketamine/xylazine
(60 mg/kg ketamine, 7.8 mg/kg xylazine) anesthesia
with supplemental doses (25 mg/kg) of ketamine when
necessary. One catheter was placed in the linguofacial
vein and the other in the submaxillary vein and threaded
to the heart. Catheters were tunneled subcutaneously and
exteriorized through a midline incision in the scalp, and
the neck incision was then sutured. Rats in the 5TG study
received an intracerebroventricular (ICV) cannula: each
rat was placed in a Kopf stereotaxic frame and a 22
gauge stainless steel guide cannula (Plastics One Inc.,
Roanoke, Virginia) was implanted, aimed at the lateral
cerebral ventricle using the stereotaxic coordinates
21.0 mm AP from bregma, ^1.6 mm ML, 24.0 mm
DV from the dura mater. Cannula patency was verified
functionally prior to the experiment by a robust 30 min
drinking response following an injection of 10 ng
angiotensin II (Sigma). IV catheters were held in place
by acrylic cement to four skull screws. Animals received
subcutaneous 1 ml Lactated Ringers solution (Baxter) and
0.2 ml Batryl antibiotic (Provet, Bayer), and were
maintained on a circulating-water heating pad until they
recovered from anesthesia. Catheter lines were filled with
25–30% polyvinylpyrrolidone (PVP10, Sigma, St. Louis
MO)/heparin (1000 units/ml; Elkins-Sinn, NJ), and kept
patent by a heparin flush (0.2 ml;100 units/ml) every
three days. All animals regained their presurgery body
weights prior to the experimental procedure (approxi-
mately seven days).
Hypoglycemia Procedure
All rats were studied in a two-day procedure. The
protocol is shown in Fig. 1. All infusions were carried out
by a programmable syringe pump (SP101i, World
Precision Instruments, FL). No food was available to
the rats during the infusion periods. On Day 1, rats
FIGURE 1 Flow chart for two-day hypoglycemia protocol. INS–
INS ¼ two insulin infusions; SAL–SAL ¼ two saline infusions on
Day 1. S/S/S ¼ Day 1 saline infusions; Day 2 saline infusion.
S/S/I ¼ Day 1 saline infusions; Day 2 insulin infusion. I/I/I ¼ Day 1
insulin infusions; Day 2 insulin infusion.



















































received two 1 h infusions of either sterile physiological
saline, or 0.675 U/100 g insulin IV (Lilly Humulin,
100 U/ml stock; infusion rate, 1.145 ml/h). A 60 min
interval separated the two infusions. All rats had chow
pellets in the experimental chambers during this hour,
and ad libitum food was available in the home cage,
following the second infusion period. On Day 2, rats
received a third infusion; blood samples (1.0 ml) were
taken at 0, 30 and 60 min and replaced with donor blood
drawn from unstressed rats immediately before the
experiment. Rats treated with insulin on Day 1 received a
third insulin infusion (I/I/I). Rats infused with saline on
Day 1 received either a third saline infusion (S/S/S) or an
insulin infusion (S/S/I). Immediately following the
60 min sample, rats were removed to a separate room
and euthanized by decapitation. Brains were rapidly
dissected ((#2 min) and brain areas for measurement of
TH activity were quick-frozen on dry ice and stored at
2808C until assay.
5-Thioglucose (5TG) Procedure
On Day 1 of the two-day protocol, food was removed at
0600 h. Rats were weight-matched and randomly
assigned to one of three injection groups. Group 1
(controls: LG/LG/LG) received two ICV injections of the
non-metabolizable glucose isomer L-glucose (1.08mmol
in 1.5ml; Aldrich Chemical Co.) 4 h apart (Day 1), and a
third L-glucose injection 24 h after the first injection (Day
2). Group 2 (LG/LG/5TG) received two injections of L-
glucose on Day 1, as described above, and an injection of
5TG (1.08mmol in 1.5ml; Sigma) on Day 2. Group 3
(5TG/5TG/5TG) received two injections of 5TG on Day
1, and a third injection of 5TG on Day 2. The 5TG dose
was based upon previous studies from Ritter and
colleagues (Slusser and Ritter, 1980). 60 min after the
ICV injection on Day 2, rats were euthanized by
decapitation and trunk blood was collected for measure-
ment of plasma glucose and corticosterone (because
these rats did not have chronic indwelling iv catheters,
catecholamines were not measured). Brains were rapidly
dissected and brain areas were quick-frozen on dry ice
and stored at 2808C, for subsequent assay of TH
activity.
Plasma Assays
Blood samples were obtained for the measurement of
neuroendocrine responses and stored at 2808C until
assayed. Blood for the catecholamine assays was collected
on EGTA:glutathione (90 mg/ml:60 mg/ml; Sigma). Tubes
for glucagon assays contained 1 M benzamidine (Sigma)
and 1 U heparin. Blood for glucose and corticosterone was
collected on EDTA. A radioenzymatic method as
described in Evans et al. (1978) was used for
determination of plasma epinephrine and norepinephrine
(intra-assay variation 6%; interassay variation 12%). A
radioimmunoassay procedure (intra-assay variation 7%;
interassay variation 15%) was used for plasma corticos-
terone measurement as described in VanDijk et al. (1997).
Glucose was determined using a modified Trinder’s
reaction assay (intra-assay variation 1%; interassay
variation 1.5%) and spectrophotometric quantitation
with a QuadFlex instrument (Titertek). Glucagon was
assayed by radioimmunoassay (Ensinck et al. (1972);
intra-assay variation 7%, interassay variation 10%).
TH Assay
TH activity was measured in freshly prepared homogen-
ates of the frozen tissue samples, utilizing the assay
procedure of Reinhard et al. (1986). The biochemical
basis for the assay is the generation and measurement of
3H2O produced by reacting
3H-tyrosine with the enzyme
present in tissue homogenates, in the presence of
exogenous excess cofactor (BH4). Brain regions were
rapidly dissected (approximately 1 min) and immediately
frozen on dry ice. Entire hypothalamus was dissected; and
the brainstem was subdissected into portions that included
the entire LC; Al; or A2 noradrenergic cell groups.
Brainstem dissections containing the Al cell group also
contained the C1 adrenergic cell group, because of the
anatomical proximity of these two nuclei. Brainstem
dissections were based on Levin and Sullivan (1979) and
atlas plates 56, 61, 64, 74, and 75 (Paxinos and Watson,
1986). Hypothalamus dissection was based on visual
landmarks as we have previously published (e.g. Baskin
et al., 1985). Frozen tissues were homogenized with a
hand-held glass homogenizer in 500ml of ice-cold 0.1%
Triton/PBS/50 mM sodium pyrophosphate. A 70 ml
aliquot of the unknown was added to 20ml of a solution
containing 1 M KH2PO4; catalase (3000 U/sample tube);
3H-tyrosine at 1mCi/sample tube (NET 127/New England
Nuclear) dried under nitrogen and resuspended in 1 mM L-
tyrosine hydrochloride (T-2006, Sigma) at a final specific
activity of 2.5 nmol/mCi; 1 M DTT; and 1 M sodium
pyrophosphate, in distilled deionized water. The reaction
was started with the addition of 10ml freshly constituted
BH4 (158 mg/ml) to each tube for a final volume of 100ml.
After vortexing, tubes were incubated for 30 min at 378C.
The reaction was stopped by the addition of 1 ml of 7.5%
charcoal (G-60 Norit). After a rapid vortex, each tube was
centrifuged 500g, 10 min. A measured amount of (2 ml)
Optifluor were added to 500ml of the clear supernatant,
and cpm were counted in a beta counter. As a positive
control between assays, an aliquot of a striatal
homogenate pool was included in each assay. Protein
was measured for each sample with a 1:12 dilution with
BCA Protein Assay Reagent (Pierce) and a microplate
spectrophotometer (Dynatech, MR 500). Efficiency of
recovery after charcoal extraction was estimated by the
cpm from samples of 100ml 3H2O that had been
centrifuged with or without charcoal addition. Activity
was calculated according to the formula: (cpm [sample] 2
cpm [blank]) £ 1000/((cpm added/2.5) £ 30 £ mg
protein £ fraction recovered). As shown in Table I,



















































assay sensitivity permits measurements of as little as 8mg
of tissue protein (#1) and demonstrates linearity with
increased protein concentration over the range of 20–
60mg for the hypothalamus; the assay also demonstrates
differences in activity which reflect the relative density of
catecholaminergic density of the tissue being assayed
(compare #1 vs. #4 in Table I). To demonstrate the
potential for increased TH activity within our hypothala-
mic homogenate preparation, a homogenate was split and
a portion pre-incubated with the cAMP analog, dibutyryl
cAMP (dbcAMP; Sigma, St. Louis MO) in vitro for 1 h.
This treatment resulted in a three-fold increase of TH
activity (compare #3 vs. #2 in Table I).
Statistical Analysis
Data from the TH assays were analyzed using repeated
measures ANOVA (RMANOVA) with brain region as the
repeated measure and treatment as the between factor. For
all of the plasma parameters, t.0 baseline data were
compared by t-test (S/S/S vs. S/S/I; S/S/S vs. I/I/I; S/S/I
vs. I/I/I). Within-subjects changes from paired t.0 baseline
values were calculated and Kruskal–Wallis analysis was
carried out to determine whether within-subjects
responses at t. 30 or 60 min were statistically significant.
Additionally, these response data (t. 30 and t. 60 time
points) were compared between groups by ANOVA, to
determine whether the changes in any plasma parameter in
response to insulin infusion (S/S/I or I/I/I) was greater than
the change which occurred in response to a control, saline
FIGURE 2 Plasma glucose levels (mg/dl) in response to Day 2 saline or insulin infusions. Upper: absolute plasma glucose values. Lower: plasma
glucose response as within-subjects change (at t. 30 and t. 60) vs. paired t.0 baseline. *p , 0:05; significant change from t.0 baseline.








Hypothalamus – 8 26.6
Hypothalamus Vehicle 21 24.9
Hypothalamus 1 mM dbcAMP (60 min) 21 75.8
Adrenal gland – 35 182
Adrenal gland – 70 186
Liver – 26 0.5























































As shown in Figs. 2 and 3, Day 1 infusion of insulin had no
effect on Day 2 baseline (t.0) values of glucose or
neuroendocrine variables, compared with those of rats
infused with saline on Day 1. Baseline (t.0) plasma
glucose concentrations did not differ among the three
groups. On Day 2, saline infusion in the S/S/S group of
rats did not significantly alter plasma glucose levels
(p ¼ 0:54 overall; Fig. 2). Epinephrine ðp ¼ 0:15Þ;
glucagon ðp ¼ 0:17Þ; corticosterone ðp ¼ 0:54Þ; and
norepinephrine ðp ¼ 0:38Þ levels also did not change
over the 60 min infusion period, relative to each animal’s
t.0 baseline (Figs. 3 and 4). In contrast, plasma glucose
levels in the S/S/I group fell significantly in response to
the 60 min insulin infusion (Fig. 2; p , 0:0001 overall).
A neuroendocrine counter-regulatory response to the
hypoglycemia was observed in the S/S/I group relative to
the S/S/S controls for glucagon ðp ¼ 0:03Þ; epinephrine
ðp ¼ 0:01Þ; norepinephrine ðp ¼ 0:03Þ; and a trend for
corticosterone ðp ¼ 0:08Þ (overall RMANOVA, Fig. 3).
This neuroendocrine response was confirmed by within-
subjects comparisons of change from individual t.0
baseline levels (Fig. 4), with overall significant elevations
of corticosterone ðp ¼ 0:003Þ; epinephrine ðp ¼ 0:005Þ;
glucagon ðp ¼ 0:04Þ; and norepinephrine ðp ¼ 0:02Þ: As
shown in Fig. 4, within-subjects epinephrine, norepi-
nephrine, and corticosterone responses were significant at
both t. 30 and t. 60; and the within-subjects glucagon
response was significant at t. 60.
Rats which had been infused with insulin on Day 1
(I/I/I) also had a highly significant decrease in plasma
glucose relative to the paired baseline (Fig. 2; p , 0:0001
overall) across the 60 min insulin infusion period, on Day
2. However, unlike the S/S/I group, there was no
significant neuroendocrine response relative to the S/S/S
control group (Fig. 3). Additionally, there was no
significant within-subjects neuroendocrine response to
the hypoglycemia (epinephrine, p ¼ 0:08; glucagon,
p ¼ 0:53; norepinephrine, p ¼ 0:19) with the exception
FIGURE 3 Absolute values for plasma glucose, corticosterone, epinephrine, glucagon, and norepinephrine on Day 2 of the two-day hypoglycemia
protocol.



















































of corticosterone ðp ¼ 0:03Þ (Fig. 4). This pattern of
blunted neuroendocrine responses, particularly the
blunted glucagon and epinephrine responses, represents
the HAAF phenomenon.
Between-group comparisons were also carried out for
the t.30 and t.60 responses of S/S/S vs. S/S/I, and S/S/S vs.
I/I/I, groups. For S/S/S vs. S/S/I comparisons, significant
overall treatment effects were observed for plasma
glucose ðp , 0:0001Þ; glucagon ðp ¼ 0:01Þ; epinephrine
ðp ¼ 0:0035Þ; and norepinephrine ðp ¼ 0:01Þ; with a non-
significant trend for corticosterone ðp ¼ 0:12Þ; perhaps
due to some variability in the corticosterone levels
within the S/S/S group. Comparisons between S/S/S and
I/I/I groups revealed a significant difference in plasma
glucose ðp ¼ 0:01Þ: However, there was no significant
treatment effect on any of the neuroendocrine parameters
measured: glucagon ðp ¼ 0:36Þ; epinephrine ðp ¼ 0:17Þ;
norepinephrine ðp ¼ 0:29Þ or corticosterone ðp ¼ 0:36Þ:
Because neuroendocrine values of the I/I/I group were
intermediate between those of the S/S/S controls, and the
S/S/I group, they also did not differ significantly from
those of the S/S/I group. Plasma glucose levels showed a
trend towards a greater decrease in the I/I/I vs. S/S/I
groups (Fig. 2) but this was not statistically significant.
TH Activity
Table II lists the absolute TH activity (pmol/min/mg) for
the three treatment groups. For ease of comparison
between treatment groups, across the four brain areas
(whose basal TH activity levels vary), TH data for the
S/S/I and I/I/I groups are shown in Fig. 5 (upper)
normalized to the corresponding S/S/S brain area, which
has been set to 100%. In response to a single bout of
hypoglycemia, there was a significant overall effect of
hypoglycemia to increase TH activity across all four brain
regions measured (S/S/S vs. S/S/I: p ¼ 0:05). Overall TH
activity in the I/I/I group did not differ from the S/S/S
FIGURE 4 Effect of Day 2 saline or insulin infusion on within-subjects plasma corticosterone, epinephrine, glucagon and norepinephrine responses.



















































group. Increases of TH activity in all of the brain areas
were modest (15–25% above S/S/S control levels). The
only brain region showing a differential effect of one vs.
multiple bouts of hypoglycemia was the hypothalamus,
where TH activity levels of the I/I/I group were equivalent
to those of controls ð108 ^ 7%Þ; in contrast to the S/S/I
group, where hypothalamic TH values were 128 ^ 14% of
the controls.
5TG Neuroglucopenia
In separate groups of rats, 5TG or control L-glucose
solutions were injected into the lateral ventricles to
achieve CNS neuroglucopenia. Success of the injections
was observed behaviorally as a development of lethargy in
the succeeding hour post-injection. Robust increases of
plasma glucose and corticosterone resulted from the Day 2
5TG injections (Fig. 6): Plasma glucose and corticoster-
one were significantly elevated by both one
([LG/LG/5TG) glucose ¼ 239 ^ 36 mg=dl; p ¼ 0:026
vs. LG/LG/LG; corticosterone ¼ 35:2 ^ 6:0mg=dl; p ¼
0:003 vs. LG/LG/LG) or three ([5TG/5TG/5TG]
glucose ¼ 278 ^ 22 mg=dl; p ¼ 2:67 £ 1027 vs.
LG/LG/LG; corticosterone ¼ 46:1 ^ 2:0mg=dl; p ¼
0:0002 vs. LG/LG/LG) injections of 5TG compared with
the LG/LG/LG controls ðglucose ¼ 136 ^
4 mg=dl; corticosterone ¼ 8:4 ^ 2:0mg=dlÞ: Glucose and
corticosterone levels did not differ between rats receiving
one vs. three bouts of CNS neuroglucopenia. The pattern
of TH activity differed from that observed in rats that were
subject to hypoglycemia (Fig. 5, lower). Rats experiencing
a single bout of neuroglucopenia did not demonstrate
activation of TH across the four brain areas assessed
(LG/LG/LG vs. LG/LG/5TG, p ¼ 0:92). However, with
the third bout of neuroglucopenia, there was a significant
increase of TH activity across brain areas (LG/LG/LG vs.
5TG/5TG/5TG, p ¼ 0:05), that may be ascribed to
increased TH activity in the A1 region and the
hypothalamus (which did not show increased TH activity
in response to the single injection of 5TG).
DISCUSSION
In this paper, we present a rodent model of acute
HAAF. Since the phenomenon of acute HAAF has been
well-documented and characterized in humans, but the
underlying mechanisms remain unknown, use of animal
models is needed to evaluate candidate mechanisms for
acute HAAF, and for the prevention of its development.
Our studies show that—similar to humans (Heller and
Cryer, 1991; Davis et al., 1996)—the rat develops an
impaired counter-regulatory response when studied in a
two-day paradigm comparable to that which has been
utilized for human studies. The rat is an experimental
FIGURE 5 TH activity in A1, A2, LC brainstem areas and whole
hypothalamus, normalized to regional TH activity in controls (set to
100%). Upper: TH activity in hypoglycemic rats (S/S/I ½n ¼ 9; cross-
hatched bars and I/I/I ½n ¼ 9; hatched bars). Lower: TH activity in
neuroglucopenic rats (LG/LG/5TG ½n ¼ 6; cross-hatched bars; and
5TG/5TG/5TG ½n ¼ 6; hatched bars).
TABLE II TH activity (pmol/min/mg) in response to hypoglycemia or
neuroglucopenia
Mean SEM Mean SEM
Hypothalamus
S/S/S 20.0 2.3 LG/LG/LG 11.8 0.9
I/I/I 21.6 1.6 5TG/5TG/5TG 18.4 3.5
S/S/I 25.5 2.6 LG/LG/5TG 12.2 1.4
Locus Coeruleus
S/S/S 5.5 1 LG/LG/LG 6.7 0.7
I/I/I 6.9 0.7 5TG/5TG/5TG 6.5 0.7
S/S/I 6.9 0.7 LG/LG/5TG 4.5 0.7
A1/C1
S/S/S 5.2 0.4 LG/LG/LG 4.4 0.6
I/I/I 6.3 0.3 5TG/5TG/5TG 5.3 0.6
S/S/I 6.5 0.6 LG/LG/5TG 5.3 0.2
A2
S/S/S 4.7 0.5 LG/LG/LG 3.5 0.3
I/I/I 5.6 0.4 5TG/5TG/5TG 3.8 0.2
S/S/I 5.4 0.6 LG/LG/5TG 3.7 0.3
S/S/S, Day 1 saline infusions, Day 2 saline infusion n ¼ 8; S/S/I, Day 1 saline
infusions, Day 2 insulin infusion n ¼ 9; I/I/I, Day 1 insulin infusions, Day 2 insulin
infusion n ¼ 9:
LG/LG/LG, Day 1 L-glucose infusions, Day 2 L-glucose infusion, n ¼ 6;
LG/LG/5TG, Day 1 L-glucose infusions, Day 2 5-thioglucose infusion n ¼ 6;
5TG/5TG/5TG, Day 1 5-thioglucose infusions, Day 2 5-thioglucose infusion n ¼ 6:



















































animal that has been well-characterized in terms of
both metabolic regulation and brain function, and thus
should continue to serve as an ideal model for studying
HAAF.
In addition to measuring neuroendocrine responses to
hypoglycemia, we measured TH activity in the brain as an
index of acute activation of brainstem NE neurons. The
increase of activity which we observed was relatively
modest (e.g. about 28% in the whole hypothalamus). This
is perhaps not surprising in light of the observation by
Pacak and colleagues that the change in measurable NE
release in hypothalamic PVN interstitial fluid in response
to a maximal hypoglycemia stimulus is less than that
observed in response to other physical stressors (Pacak
et al., 1995b), and presumptively, acute stimulation of TH
activity will correspond to the extent of drive for release
of NE at the synaptic terminal. Similarly, Beverly et al
have recently demonstrated relatively modest increases of
hypothalamic NE release in their model of insulin-
induced hypoglycemia (Beverly et al., 2001). It should be
acknowledged that the hypothalamus also has intrinsic
dopamine neurons, and receives adrenergic projections
from brainstem adrenergic neurons; TH activity would
reflect the composite of these three types of nerve
terminals. Moore and Lookingland (1995) have summar-
ized evidence that intrinsic hypothalamic dopaminergic
activity is, in fact, suppressed in association with stress.
Thus, our findings which show an overall increase of TH
activity in the brain areas that contain NE cell bodies and
in the hypothalamus, are supportive of the interpretation
that hypoglycemia acutely increases noradrenergic
(and perhaps adrenergic) signaling to the hypothalamus.
The specific loci within the hypothalamus remain to
be determined since TH was measured in the entire
hypothalamus; it is possible that our measurement reflects
activation in very discrete areas such as the PVN, which is
then masked when activity is normalized against the total
protein content of the entire hypothalamus. The
hypothalamic TH activity in rats with prior experience
of hypoglycemia (I/I/I) was identical to that of saline-
treated controls (S/S/S). This was not observed in the
three NE cell body regions (Al/C1, A2, and LC) and
suggests that there may be a local suppression of TH
activity (and thus, catecholaminergic activation) within
the hypothalamus in association with HAAF.
Use of 5TG to induce cerebral neuroglucopenia
provides some insight into the mechanism(s) of acute
HAAF. Specifically, both corticosterone and TH measure-
ments in the neuroglucopenic animals suggest that the
stimulus of insulin-induced hypoglycemia is not an
identical stimulus to CNS neuroglucopenia. Although
peripheral corticosterone levels were elevated with one
bout of neuroglucopenia (the LG/LG/LG group) to a
comparable degree as they were with hypoglycemia, the
corticosterone response to a third bout of neuroglucopenia
within a 24 h period was not impaired. The pattern of TH
activity was also different between the hypoglycemia and
neuroglucopenia models, both in the groups receiving only
one metabolic insult, and in those receiving the recurrent
insult. A recent study from Rusnak et al. (1998) reports
differential effects of insulin-induced hypoglycemia and
peripherally-induced neuroglucopenia on induction of TH
gene expression in the LC cell bodies and in the adrenal
medulla, which supports our conclusion that these two
metabolic stressors are not an equivalent stimulus to
the CNS. Also, patterns of NE release within the
FIGURE 6 Effect of one or three bouts of neuroglucopenia on plasma glucose and CORT responses. Data are expressed as percent of L-glucose treated
controls (LG/LG/LG). Cross-hatched bars represent rats receiving one bout of neuroglucopenia (LG/LG/5TG, n ¼ 6); hatched bars represent rats
receiving three bouts of neuroglucopenia (5TG/5TG/5TG, n ¼ 6).



















































hypothalamus differ both quantitatively and qualitatively
in insulin-induced hypoglycemia and 2-deoxyglucose-
induced neuroglucopenia (Beverly et al., 2000; 2001). The
corticosterone data in this study also suggest that although
prior elevations of corticosterone may contribute to the
development of acute HAAF, as proposed by Davis et al.
(1996), corticosterone cannot be the sole mechanistic
factor involved. If so, one would have predicted that the
neuroendocrine response to a third bout of CNS
neuroglucopenia would be blunted as is the neuroendo-
crine response to recurrent hypoglycemia. This conclusion
is supported by our own recent observation in a slightly
modified HAAF paradigm, in which intracerebral
corticosterone (Day 1) did not blunt neuroendocrine
responses to insulin-induced hypoglycemia on Day 2
(Evans et al., 2001).
A major difference between the models in this study is
the treatment route. Hypoglycemia develops peripherally
and thus peripheral tissues in addition to the brain are
exposed to a lack of glucose. In contrast, with CNS
administration of 5TG, only the brain receives the
neuroglucopenic stimulus and the peripheral tissues
never experience a lack of glucose. One might conclude
therefore, that peripheral afferent information plays a
critical role in mediating the activation of TH in response
to hypoglycemia, and the absence of ascending inputs may
be responsible for the lack of stimulation observed in the
hypothalamus in response to a single bout of CNS
neuroglucopenia. It is well-documented that glucose-
sensing neurons are present in the hypothalamus (Levin
et al., 1999). Thus, activation of the HPA response to
specific CNS neuroglucopenia may be occurring via other
pathways, perhaps being initiated directly within the
hypothalamus. This is supported by the studies from Borg
et al. (1995; 1997) that demonstrate the direct infusion of
the neuroglucopenic agent 2-deoxyglucose (2DG) into the
ventromedial nucleus of the hypothalamus (VMH) results
in activation of a neuroendocrine counter-regulatory
response; and glucose infusion into the VMH can reverse
the counter-regulatory response to peripherally-induced
neuroglucopenia. Peripheral administration of 2DG can
result in increased c-fos immunoreactivity in brainstem
catecholamine neurons (an index of neuronal activation)
in brainstem catecholaminergic neurons (Ritter and
Dinh, 1994; Sanders and Ritter, 2000). Insulin-induced
hypoglycemia has been reported not to result in increased
c-fos expression in these neurons (Baffi et al., 1996).
This provides further evidence, with another marker
of neuronal responsivity, that insulin hypoglycemia
and neuroglucopenia may represent different stimuli to
the CNS.
Sanders and Ritter (2000) have recently reported that
both brainstem c-fos activation and counter-regulatory
responses to subcutaneous 2DG were blunted in animals
pretreated with 10 daily injections of 2DG. This time
course would allow for adaptive changes such as gene and
protein expression in nerve terminals, or perhaps altered
efficiency of glucose uptake by the CNS, as has been
reported by Doyle et al. (1995). The occurrence of such
adaptive changes may result in a change in the signal or
stimulus at the CNS, although the amount of 2DG given
was held constant; thus, it might be expected that the
response to a subsequent 2DG challenge would be
blunted. Our study suggests that the model presented here
is one of very acute HAAF, independent of chronic
adaptive changes, and acute HAAF may thus represent a
unique variation of the stress adaptation syndrome.
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